AI Terminal
INTELLIGENT ULTRASOUND GROUP PLC
Board/Management Information • Sep 16, 2020
7714_rns_2020-09-16_40fdc5c1-20c3-4390-a7f9-fb0ca8544b10.html
Board/Management Information
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 0924Z
Intelligent Ultrasound Group PLC
16 September 2020
Intelligent Ultrasound Group plc
("Intelligent Ultrasound" or the "Company")
Formation of Nomination Committee
Intelligent Ultrasound (AIM: MED), the artificial intelligence (AI) based ultrasound software and simulation company, announces the formation of a Nomination Committee of The Board of Directors.
While to date, Intelligent Ultrasound has used the whole board to consider matters of nomination, given the Company's current maturity and the nature of its current board composition, the Company is establishing a more focused Nomination Committee to lead its process for appointments and oversee the development of a diverse pipeline for succession.
As set out in its chosen governance code, the QCA's Corporate Governance Code (the "Code"), the Nomination Committee will seek "to identify the skills, experience, personal qualities and capabilities required for the next stage in the company's development, linking the company's strategy to future changes on the board"
As required by the Code, details of the Terms of Reference for the Intelligent Ultrasound Nomination Committee can be found on the Company's website www.intelligentultrasoundgroup.com/directors-and-committees
Riccardo Pigliucci, Non-Executive Chairman, said:
"Intelligent Ultrasound is transitioning from the typical Founders and Venture driven company to a more mature public entity and as such it is time to reconfigure our Board to comply with both the independence and the seniority requirement of today's public companies. I look forward to updating investors over time on new independent non-executive director appointments and Board changes as they become effective."
For further information, please contact:
| Intelligent Ultrasound Group plc | www. intelligentultrasound.com | |
| Stuart Gall, CEO Helen Jones, Group Finance Director |
Tel: +44 (0)29 2075 6534 | |
| Cenkos Securities - Nominated Advisor and Broker | Tel: +44 (0)20 7397 8900 | |
| Giles Balleny / Cameron MacRitchie (Corporate Finance) | ||
| Michael Johnson / Julian Morse (Sales) | ||
| Walbrook PR | Tel: +44 (0)20 7933 8780 or [email protected] | |
| Anna Dunphy / Paul McManus | Mob: +44 (0)7876 741 001 / Mob: +44 (0)7980 541 893 | |
About Intelligent Ultrasound Group
Intelligent Ultrasound (AIM: MED) develops artificial intelligence-based clinical image analysis software tools for the diagnostic medical ultrasound market and hi-fidelity virtual reality simulators for the ultrasound training market.
Based in Cardiff in the UK, Atlanta in the US and with representation in Beijing in Asia, the Group operates two divisions:
Clinical AI Division
Focusses on developing deep learning-based algorithms to make ultrasound machines smarter and more accessible. Products in development include ScanNav which uses machine-learning based algorithms to automatically identify and grade ultrasound images to provide scan assessment and audit of protocol-based ultrasound scanning; and AnatomyGuide, which aims to simplify ultrasound-guided needling by providing the user with real-time AI-based needle guidance software for a range of medical procedures.
Simulation Division
Focusses on hi-fidelity ultrasound education and training through simulation. Its three main products are the ScanTrainer OBGYN training simulator, the HeartWorks echocardiography training simulator and the BodyWorks Eve Point of Care and Emergency Medicine training simulator. To date over 900 simulators have been sold to almost 500 medical institutions around the world.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
MSCSFSFWIESSEFU